Loading...

Daily news and top headlines for life science research professionals

FREE Email Newsletter View Sample


Equity Brief: Ratings Changes for November 6th: JMBA, KMP, KRFT, LIFE, LNKD, LRCX, LSI, MDF, MDLZ

By The Associated Press Tuesday, November 6, 2023

See today's top life science stories and headlines - Sign up now!

newsvine diigo google
slashdot
Share
Loading...

A number of stocks were upgraded and downgraded by equities research analysts today, as reported by Analyst Ratings Network (http://bit.ly/equitybriefdaily) and Equity Brief:

Canaccord Genuity reiterated its buy rating on shares of Jamba, Inc. (JMBA). They have a $3.00 price target on the stock.

Zacks reiterated its neutral rating on shares of Kinder Morgan Energy Partners LP (KMP). They have a $87.00 price target on the stock. Zacks' analyst wrote, "We are maintaining our Neutral recommendation for Kinder Morgan following the third quarter 2012 results. The partnership delivered positive performances across each of its business segments. But more importantly, management hiked its quarterly cash distribution rate by 9% year-over-year. We expect Kinder Morgan to seize attractive investment opportunities in the near term, particularly in the Eagle Ford and Haynesville shale plays. However, the partnership remains vulnerable to macro conditions, unstable oil & gas prices and interest rate fluctuations. Therefore, we see limited upside potential and are sticking with our prior recommendation."

Canaccord Genuity initiated coverage on shares of Kraft Foods (KRFT). They issued a buy rating on the stock.

Zacks reiterated its neutral rating on shares of Life Technologies Corporation (LIFE). They have a $51.00 price target on the stock. Zacks' analyst wrote, "Life's third quarter adjusted EPS of $0.92 surpassed the Zacks Consensus Estimate of $0.89 but missed the year-ago quarter's $0.94. Revenues increased 1.4% at CER to $911 million, ahead of the Zacks Consensus Estimate of $908 million. The Ion Torrent franchise recorded strong growth, based on portfolio expansion including the recent launch of Ion Proton system. However, economic uncertainties and unfavorable currency were the major headwinds for Life during the reported quarter. The company tightened its 2012 earnings outlook and expects organic revenue growth at 2%. The company, however, plans to offset a portion of the headwinds through lower discretionary spending and marginally lower tax rate. We are also impressed by the company's capital deployment policy. As a result, we maintain our Neutral' recommendation on the stock. "

Zacks reiterated its neutral rating on shares of Linkedin Co. (LNKD). They have a $112.00 price target on the stock. Zacks' analyst wrote, "The third quarter numbers were encouraging and revenues were considerably higher across segments. Also, earnings exceeded our expectation. LinkedIn commands a dominant position in the emerging online professional networking segment. The company has attained worldwide popularity and has grown steadily over the last few quarters. The Talent Solutions and Premium Subscription segments were particularly strong. Cost-control measures were implemented effectively to improve its bottom line. LinkedIn's current competitive pressure is not severe in the professional networking space. However, competition is picking up as companies such as Facebook, Google and Microsoft are expected to enter the market soon. Hence, the competitive scenario could change rapidly over the next few years. "

Susquehanna upgraded shares of Lam Research Co. (LRCX) from a neutral rating to a positive rating. Susquehanna now has a $48.00 price target on the stock, up previously from $32.00.

Zacks reiterated its neutral rating on shares of LSI Co. (LSI). They have a $7.00 price target on the stock. Zacks' analyst wrote, "We believe that LSI Corp is well positioned to grow its market share based on its new product cycles that will enable it to outgrow its storage and networking markets. Over the last two years, LSI Corp. has invested heavily on a number of product lines, some of which have started contributing to the top line. LSI Corp. recently reported in line results in the third quarter but provided soft guidance for the fourth quarter leading to a decline in earnings estimates. Demand continues to be weak due to the economic uncertainty. Consequently, LSI Corp. expects to witness lower demand for components in the fourth quarter, resulting from the ongoing softness in the PC end market. Both custom and standard products along with flash storage processors are estimated to decline. Hence, we maintain a Neutral recommendation."

Sidoti downgraded shares of Metropolitan Health Networks, Inc. (MDF) from a buy rating to a neutral rating.

Feltl & Co. downgraded shares of Metropolitan Health Networks, Inc. (MDF) from a buy rating to a hold rating. They wrote, "Metropolitan Health Networks announced this morning it entered into a definitive merger agreement with Humana (HUM - not rated) to be acquired for $850 million or $11.25 per share. The companies expect this acquisition to close by the end of the first quarter in 2013. . We are increasing our price target to the acquisition price of $11.25 and lowering our rating to HOLD from STRONG BUY. Given we do not believe it is likely for any competing bids to surface we encourage investors to use MDF as a source of funds if other investments provide attractive opportunities."

Northland Securities raised its price target on shares of Medifast, Inc. (MED) from $29.00 to $34.00. They have an outperform rating on the stock.

Stay on top of analysts' coverage with Analyst Ratings Network's free daily email newsletter that provides a concise list of analysts' upgrades, downgrades and initiations. Register at http://bit.ly/equitybriefdaily

Content and Media Contact: newseditor@equitybrief.net

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Equity Brief via Thomson Reuters ONE

HUG#1655492

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Live Cell Analysis of Autophagy

Analysis of autophagosome formation using fluorescent cellular imaging and lentiviral biosensors.

Deconstructing 3D Cell Culture

3D culture models offer the potential to significantly reduce drug failure.

Safety Without Sacrifice

Safety Without Sacrifice

Liquid handling ergonomics and performance considerations

ELNs: The Beating Heart of a Scientist’s World

ELNs: The Beating Heart of a Scientist’s World

As ELNs deliver more benefits to researchers, the cost of changing working practice is outweighed by access to high quality, high context collaboration.

Evaluation of a New Nano-Type UV-Vis Spectrophotometer

Analysis of one- to four-microliter size samples for nucleic acids has become routine in many life science laboratories. However, until now, available instruments require considerable manipulation of the instrument and sample; some require manually recording the data. The user must typically lower and raise the arm manually, then wipe the sample manually from the target after each analysis. And fiberoptics used in some of these instruments are subject to deterioration.

Production of Recombinant Proteins and Monoclonal Antibodies in Hollow Fiber Bioreactors

While well-understood, robust and convenient, classical batch-style 2-D culture on non-porous supports or 3-D suspension culture in other devices are really not very biologically relevant models. Cell culture conditions can affect the quality of the antibody or protein produced.

Selecting Robots for Use in Drug Discovery and Testing

Drug discovery and testing, with their need for speed, repeatability and verification, are ideally suited to benefit from robot automation. It is therefore not surprising that robots have been at the forefront of automation developments in both these areas.

HP Scalable Network Storage Systems for Life Sciences

Life sciences research today is advancing exponentially, each step bringing us closer to the realization of truly personalized medicine–preventive care and treatments designed specifically for each individual. In the near future, PCPGM healthcare researchers expect to be able to use predictive genetic testing to create custom treatment plans for individuals and deliver dramatic improvements over today’s one-size-fits-all approach. But research capabilities are only part of the equation; current storage and operating capacities must also evolve to accommodate ever-expanding amounts of data before the goal of personalized medicine can be realized.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
Loading...

Free Life Science Industry
Subscriptions

Magazine

wireless week

Newsletters

newsletters

Sign up now



MULTIMEDIA

Video:

Epigenetics

Aug 30

Hank & his clone Circus Hank explain the power of epigenetics, which studies the factors that determine how much or whether some genes are expressed in your body.

Podcasts:

Futures In Biotech 93: Snyder's Omics

May 17

Host: Marc Pelletier Co-Host: Andre Nantel, Ph.D. The technologies that our guest has developed are playing an important role in changing the world, not like the car, the microwave and the cell phone, but as in Drs. Flox, McCoy, and Crusher. Guest: Dr. Michael Snyder We invite...

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter

Information: